We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Combimatrix Corp. (MM) | NASDAQ:CBMX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.25 | 0.05 | 6.75 | 0 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Amendment No. 1 to
SCHEDULE 14D-9
(Rule 14d-101)
Solicitation/Recommendation Statement under Section 14(d)(4)
of the Securities Exchange Act of 1934
CombiMatrix Corporation
(Name of Subject Company)
CombiMatrix Corporation
(Names of Persons Filing Statement)
Series F Warrants to Purchase Common Stock, Par Value $0.001 Per Share
(Title of Class of Securities)
20009T147
(CUSIP Number of Class of Securities)
Mark McDonough
President and Chief Executive Officer
CombiMatrix Corporation
300 Goddard, Suite 100
Irvine, CA 92618
(949) 753-0624
(Name, address and telephone number of person authorized to receive notices and communications on behalf of the persons filing statement)
Copies to:
Thomas Brida General Counsel Invitae Corporation 1400 16th Street San Francisco, CA 94103 (415) 350-3618 |
Mike Hird Patty M. DeGaetano Pillsbury Winthrop Shaw Pittman LLP 12255 El Camino Real, Suite 300 San Diego, CA 92130 (619) 234-5000 |
Mark McDonough President and Chief Executive Officer CombiMatrix Corporation 300 Goddard, Suite 100 Irvine, CA 92618 (949) 753-0624 |
Parker A. Schweich Stradling Yocca Carlson & Rauth, P.C. 660 Newport Center Drive, Suite 1600 Newport Beach, CA 92660 (949) 725-4000 |
[ ] | Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. |
This Amendment No. 1 (this “Amendment”) amends and supplements the Solicitation/Recommendation Statement on Schedule 14D-9 (as amended, the “Schedule 14D-9”) originally filed on September 14, 2017. This Schedule 14D-9 relates to the offer by Invitae Corporation, a Delaware corporation (“Invitae”), to exchange (the “Exchange Offer”) each outstanding Series F warrant (the “CombiMatrix Series F Warrants”) to acquire shares of common stock of CombiMatrix Corporation, a Delaware corporation (“CombiMatrix”), for shares of common stock, par value $0.0001 per share, of Invitae (the “Invitae Common Stock”), as disclosed in the Amendment No. 1 to Tender Offer Statement on Schedule TO (together with the exhibits thereto, as amended, the “Schedule TO”), filed by Invitae with the Securities and Exchange Commission (the “SEC”) on September 28, 2017.
The terms and conditions of the Exchange Offer, as well as a description of CombiMatrix and other information required by Schedule 14D-9, are set forth in the prospectus/offer to exchange, dated September 28, 2017 (the “Prospectus/Offer to Exchange”), which is part of Amendment No. 1 to Registration Statement on Form S-4 (File No. 333-220448) (as amended, the “Registration Statement”) that Invitae filed with the SEC on September 28, 2017, and which, with the related Letter of Transmittal filed as Exhibit 99.1 to the Registration Statement, together constitute the “Offer.” The Prospectus/Offer to Exchange is incorporated herein by reference in its entirety.
Pursuant to the Exchange Offer, each CombiMatrix Series F Warrant validly tendered and not withdrawn in the Exchange Offer will be exchanged for a number of shares of Invitae Common Stock (the “Warrant Exchange Ratio”) equal to 0.3056, which was calculated as the quotient (rounded to the nearest ten-thousandth) obtained by dividing $2.90 by the average closing price of $9.491 for shares of Invitae common stock on the NYSE for the immediately preceding period of 30 trading days prior to July 31, 2017, the date of the Agreement and Plan of Merger and Reorganization by and among Invitae, Coronado Merger Sub, Inc. and CombiMatrix.
Items 1 through 8.
All of the information in the Prospectus/Offer to Exchange, and any prospectus supplement or other amendment or supplement thereto related to the Exchange Offer hereafter filed with the SEC by Invitae, is hereby incorporated by reference into Items 1 through 8 of this Schedule 14D-9. This Amendment should be read together with the Schedule 14D-9.
Item 9. Exhibits.
* Incorporated by reference to the Registration Statement or the Schedule TO.
SIGNATURES
After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
COMBIMATRIX CORPORATION | ||
Dated: September 29, 2017 | By: |
/s/ SCOTT R. BURELL |
Name: | Scott R. Burell | |
Title: | Chief Financial Officer |
1 Year Combimatrix Corp. (MM) Chart |
1 Month Combimatrix Corp. (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions